We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Chuck Grassley (R-Iowa), chairman of the Senate Finance Committee, recently wrote a letter to FDA Acting Commissioner Andrew von Eschenbach questioning why the agency would allow a company to test a blood substitute on trauma patients in 18 states without meaningful patient consent.
Andrew von Eschenbach, the FDA's acting commissioner, will soon be nominated to take over the job permanently, according to several industry sources who applauded the move as a step toward reforming the FDA's drug-safety and approval programs.
Former FDA Commissioner Lester Crawford, who is currently under an HHS investigation, has joined a Washington, D.C., lobbying firm that specializes in advocating for clients in the biotechnology, drug and medical device industries.
David Horowitz, the FDA’s director of the Office of Compliance, has accepted a position as the deputy associate commissioner for compliance policy in the Office of Regulatory Affairs (ORA), the agency announced late Jan. 11.